MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Cogent Biosciences Inc

Chiusa

10.42 7.31

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

9.3

Massimo

10.92

Metriche Chiave

By Trading Economics

Entrata

-4.1M

-72M

Dipendenti

205

EBITDA

-1.2M

-74M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+90.59% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

430M

1.1B

Apertura precedente

3.11

Chiusura precedente

10.42

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 lug 2025, 15:46 UTC

I principali Market Mover

BitMine Shares Fall After Closing of $250 Million Private Placement

9 lug 2025, 23:44 UTC

Discorsi di Mercato

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 lug 2025, 23:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

9 lug 2025, 23:42 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 lug 2025, 22:59 UTC

Discorsi di Mercato

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 lug 2025, 22:59 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

9 lug 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

9 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 lug 2025, 20:26 UTC

Utili

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 lug 2025, 19:18 UTC

Discorsi di Mercato

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 lug 2025, 19:03 UTC

Discorsi di Mercato

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 lug 2025, 18:31 UTC

Discorsi di Mercato

Some Fed Officials Supported Considering July Cut -- Market Talk

9 lug 2025, 17:07 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 lug 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk -2-

9 lug 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

9 lug 2025, 16:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Health Care Roundup: Market Talk

9 lug 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 lug 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

9 lug 2025, 16:14 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

9 lug 2025, 16:14 UTC

Discorsi di Mercato

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 lug 2025, 16:14 UTC

Acquisizioni, Fusioni, Takeovers

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 lug 2025, 16:12 UTC

Discorsi di Mercato

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 lug 2025, 16:08 UTC

Discorsi di Mercato

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 lug 2025, 15:31 UTC

I principali Market Mover

BitMine Shares Fall After Closing of $250M Private Placement

9 lug 2025, 15:31 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 lug 2025, 15:27 UTC

Discorsi di Mercato

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 lug 2025, 14:36 UTC

Acquisizioni, Fusioni, Takeovers

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 lug 2025, 14:31 UTC

Acquisizioni, Fusioni, Takeovers

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 lug 2025, 14:26 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

9 lug 2025, 14:26 UTC

Discorsi di Mercato

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

90.59% in crescita

Previsioni per 12 mesi

Media 18.64 USD  90.59%

Alto 28 USD

Basso 9 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

9

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Strong Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.